文献速递心血管胸部乳腺CT

应用冠状动脉计算机断层扫描血管成像纵向评估乳腺癌患者的冠状动脉与心肌

Longitudinal Evaluation of Coronary Arteries and Myocardium in Breast Cancer Using Coronary Computed Tomographic Angiography.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-07-10

前瞻性纳入接受蒽环类药物联合或不联合放疗的左乳腺癌患者,于治疗前后行冠状动脉CTA(含钙化积分、CTA及双能延迟强化扫描)。治疗后CT-FFR降低、PCAT CT衰减及左心室全局与节段ECV升高;基线冠状动脉狭窄及CT-FFR与癌症治疗相关心功能障碍相关。

要点

  • 治疗后CT-FFR降低,PCAT CT衰减和左心室全局及节段ECV升高(均P<0.05)。
  • 放化疗后CT-FFR低于化疗后,PCAT CT衰减和左心室心肌ECV高于化疗后。
  • 基线LAD、LCX、RCA狭窄及CT-FFR与癌症治疗相关心功能障碍相关。

核心结论

  • 多参数冠状动脉CTA有助于全面评估接受蒽环类药物联合或不联合放疗的左乳腺癌患者的冠状动脉和心肌;基线冠状动脉狭窄和CT-FFR可能作为预测此类患者癌症治疗相关心功能障碍的影像标志物。

研究设计与样本

  • 前瞻性纳入接受蒽环类药物联合或不联合放疗的左乳腺癌患者,共80例接受蒽环类药物、59例接受蒽环类药物联合放疗;所有参与者治疗前后行冠状动脉CTA,包括非增强钙化积分扫描、CT血管成像和双能延迟强化扫描;比较治疗前后CT-FFR、PCAT CT衰减和左心室节段ECV;采用逻辑回归分析基线冠状动脉CTA参数与癌症治疗相关心功能障碍的关联。

关键影像表现/征象

  • 治疗后CT-FFR降低,PCAT CT衰减及左心室全局和节段ECV升高(均P<0.05)。
  • 放化疗后CT-FFR低于化疗后,PCAT CT衰减和左心室心肌ECV高于化疗后。

诊断标准与关键数值

  • 经心脏衰竭协会-国际心脏肿瘤学会风险校正后,基线LAD狭窄与癌症治疗相关心功能障碍相关(OR:1.987 [95%CI:1.322-2.768];P=0.021)。
  • 经心脏衰竭协会-国际心脏肿瘤学会风险校正后,基线LCX狭窄与癌症治疗相关心功能障碍相关(OR:1.895 [95%CI:1.281-2.802];P=0.031)。
  • 经心脏衰竭协会-国际心脏肿瘤学会风险校正后,基线RCA狭窄与癌症治疗相关心功能障碍相关(OR:1.920 [95%CI:1.405-2.811];P=0.028)。
  • 经心脏衰竭协会-国际心脏肿瘤学会风险校正后,基线LAD的CT-FFR与癌症治疗相关心功能障碍相关(OR:3.425 [95%CI:1.621-9.434];P<0.001)。
  • 经心脏衰竭协会-国际心脏肿瘤学会风险校正后,基线LCX的CT-FFR与癌症治疗相关心功能障碍相关(OR:2.058 [95%CI:1.030-5.076];P=0.006)。

临床应用与阅片要点

  • 对接受蒽环类药物联合或不联合放疗的左乳腺癌患者,冠状动脉CTA可同时评估冠状动脉狭窄、CT-FFR、PCAT CT衰减及左心室心肌ECV。
  • 基线冠状动脉狭窄和CT-FFR可能是预测癌症治疗相关心功能障碍的影像标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The association of coronary computed tomography angiography (CTA) and left ventricular (LV) myocardium measurements with cancer therapy-related cardiac dysfunction (CTRCD) is limited.

OBJECTIVES: In this study, the authors sought to evaluate the changes in coronary arteries and LV myocardium in patients with left breast cancer (BC) receiving anthracycline with or without radiotherapy, with the use of coronary CTA.

METHODS: Participants with left BC receiving anthracycline with or without radiotherapy were prospectively included. All participants underwent coronary CTA before and after treatment, including nonenhanced calcium-scoring scan, computed tomography angiography, and dual-energy late enhancement scan. Computed tomographic fractional flow reserve (CT-FFR), pericoronary adipose tissue (PCAT) CT attenuation, and LV segments' extracellular volume (ECV) before and after treatment were compared. Logistic regression analysis was used to assess the association between baseline coronary CTA parameters and CTRCD.

RESULTS: Eighty participants receiving anthracycline and 59 participants receiving anthracycline with radiotherapy were included. CT-FFR decreased and PCAT CT attenuation and LV global and segments' ECV increased after treatment (all P < 0.05). After chemoradiotherapy, CT-FFR was lower and PCAT CT attenuation and LV myocardial ECV were higher than after chemotherapy. Twenty-four participants developed CTRCD. After adjustment by Heart Failure Association-International Cardio-Oncology Society risk in multivariable logistic regression analysis, baseline stenosis of the left anterior descending artery (LAD) (OR: 1.987 [95% CI: 1.322-2.768]; P = 0.021), left circumflex artery (LCX) (OR: 1.895 [95% CI: 1.281-2.802]; P = 0.031), and right coronary artery (RCA) (OR: 1.920 [95% CI: 1.405-2.811]; P = 0.028), and baseline CT-FFR of the LAD (OR: 3.425 [95% CI: 1.621-9.434]; P < 0.001), LCX (OR: 2.058 [95% CI: 1.030-5.076]; P = 0.006), and RCA (OR: 2.469 [95% CI: 1.232-6.944]; P = 0.004) were associated with CTRCD.

CONCLUSIONS: Multiparameter coronary CTA contributes to comprehensive assessment of the coronary arteries and myocardium in patients with left BC receiving anthracycline with or without radiotherapy. Baseline coronary artery stenosis and CT-FFR might be imaging markers for predicting CTRCD in these patients.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Tu C, Shen H, Li X, et al. Longitudinal Evaluation of Coronary Arteries and Myocardium in Breast Cancer Using Coronary Computed Tomographic Angiography. JACC Cardiovasc Imaging. 2024. PMID: 39001732. doi:10.1016/j.jcmg.2024.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。